Comparable stake leader
Frankenius Equity AB
SEC ownership of TriSalus Life Sciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001826667.
Disclosed value leader
MedTech Acquisition Sponsor LLC
Comparable rows
6/50
Latest evidence
05 Oct 2026
- Public ticker
- TLSI, TLSIW on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Frankenius Equity AB
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Frankenius Equity AB
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
05 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001826667
- Issuer location
- Westminster, CO
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of TriSalus Life Sciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frankenius Equity AB
Disclosed value leader
MedTech Acquisition Spons...
Comparable rows
6/50
Latest evidence
05 Oct 2026
13D/G
3/4/5
13F
Lead comparable stake: 14%
44 rows are not safely comparable across share classes.
13D/G row: Frankenius Equity AB
Showing 1-8 of 50 holder rows.
Quick read
Frankenius Equity AB leads the comparable SEC ownership view at 14%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frankenius Equity AB's linked filing trail.
Comparable ownership
Top 5
Frankenius Equity AB
14%
First Light Asset Management, LLC
11%
Mats Wahlstrom
6%
Utmost Group Plc
5.7%
James J. Pallotta
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frankenius Equity AB |
13D/G
3/4/5
10%+ Owner
|
14%
Reported 13D/G
· 31 Jul 2025
|
$34,179,868
6,989,748 shares
|
+$1,257,864 | 31 Jul 2025 |
| First Light Asset Management, LLC |
13F
13D/G
Company
|
11%
Reported 13D/G
· 30 Jun 2026
|
$29,813,834
6,552,491 shares
|
— | 30 Jun 2026 |
| Mats Wahlstrom |
13D/G
3/4/5
Director
|
6%
Reported 13D/G
· 31 Jul 2025
|
$14,610,738
2,987,881 shares
|
+$931,271 | 31 Jul 2025 |
| Utmost Group Plc |
13D/G
|
5.7%
Reported 13D/G
· 31 Mar 2026
|
$14,644,149
3,503,385 shares
|
+$493,867 | 31 Mar 2026 |
| James J. Pallotta |
13D/G
|
5.2%
Reported 13D/G
· 15 May 2026
|
$14,444,861
3,188,711 shares
|
$0 | 15 May 2026 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
4.1%
Reported 13D/G
· 30 Sep 2025
|
$9,487,139
2,040,245 shares
|
+$187,139 | 30 Sep 2025 |
| MedTech Acquisition Sponsor LLC |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$65,538,115
6,250,000 shares
mixed-class rows
|
— | 26 Jun 2023 |
| Magnetar Financial LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$174,782
16,668 shares
|
— | 12 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$3,466,996.
Buys
$3,606,918
Insiders: 6
Sells
$139,922
Insiders: 5
Net
+$3,466,996
Shares: +1,127,107
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,162,267
Shares: 35,160
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 937 | $0 | $4,113 | -$4,113 |
| 3-6 | 726,782 | 543 | $1,821,429 | $1,450 | +$1,819,980 |
| 6-9 | 435,485 | 33,680 | $1,785,488 | $134,358 | +$1,651,130 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to TriSalus Life Sciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
MedTech Acquisition Sponsor LLC
Net 12M change
+$3.47M
Full value: +$3,466,998 · USD · 12-month changeLatest report
05 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| MedTech Acquisition Sponsor LLC | 10%+ Owner | $65,538,115 | Mixed | 26 Jun 2023 | ||
| Frankenius Equity AB | 10%+ Owner | $27,190,119 | Mixed | 31 Jul 2025 | ||
| Mats Wahlstrom | Director | $11,631,214 | +$151,800 | +1.3% | Mixed | 15 May 2026 |
| Kerry R. Hicks | Director | $9,269,600 | Mixed | 14 May 2026 | ||
| David J. Matlin | Director | $5,292,840 | Mixed | 14 May 2026 | ||
| Michael P. Stansky | Director | $4,919,811 | +$3,005,502 | +157% | Filing P/S | 15 May 2026 |
| Szela Mary T. | CEO and President, Director | $4,891,204 | +$148,390 | +3.1% | Mixed | 05 Oct 2026 |
| Sean Murphy | Director | $3,818,390 | Mixed | 12 Jun 2025 | ||
| George Kelly Martin | Director | $1,359,468 | Filing P/S | 28 Aug 2024 | ||
| David Patience | Chief Financial Officer | $1,044,428 | +$32,247 | +3.2% | Mixed | 01 Jul 2026 |
| Arjun Jj Desai | Director | $911,899 | Filing P/S | 12 Jun 2025 | ||
| Bryan F. Cox | Chief of Research | $714,713 | -$14,385 | -2% | Filing P/S | 05 Oct 2026 |
| Richard Marshak | Chief Commercial Officer | $561,893 | -$17,086 | -3% | Filing P/S | 05 Oct 2026 |
| Jennifer Stevens | Chief Regulatory Officer | $543,455 | -$15,896 | -2.8% | Filing P/S | 05 Oct 2026 |
| James Alecxih | President, Device Technology | $521,147 | Mixed | 10 Aug 2023 | ||
| James Emmett Young | Chief Financial Officer | $428,854 | Mixed | 19 May 2025 | ||
| Jodi Devlin | Chief of Clinical Operations | $401,139 | -$13,171 | -3.2% | Filing P/S | 11 Mar 2026 |
| Steven C. Katz | Chief Medical Officer | $377,229 | Mixed | 12 Feb 2024 | ||
| Richard Henry Marshall | Chief Medical Officer | $360,000 | Mixed | 29 Jun 2026 | ||
| William Valle | Director | $332,964 | +$124,997 | +60% | Mixed | 14 May 2026 |
Recent insider transactions for TriSalus Life Sciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Bryan F. Cox | TLSI | Common Stock | Sale | -0.18% | -$1,299 | $4.39 | -296 | 162,805 | 05 Oct 2026 | Direct |
| Richard Marshak | TLSI | Common Stock | Sale | -0.25% | -$1,427 | $4.39 | -325 | 127,994 | 05 Oct 2026 | Direct |
| Jennifer Stevens | TLSI | Common Stock | Sale | -0.25% | -$1,387 | $4.39 | -316 | 123,794 | 05 Oct 2026 | Direct |
| Szela Mary T. | TLSI | Common Stock | Tax liability | -0.25% | -2,693 | 1,074,990 | 05 Oct 2026 | Direct | ||
| David Patience | TLSI | Common Stock | Tax liability | -5.31% | -14,650 | 261,107 | 01 Jul 2026 | Direct | ||
| Szela Mary T. | TLSI | Common Stock | Award | 0.37% | 3,990 | 1,077,683 | 30 Jun 2026 | Direct | ||
| Richard Marshak | TLSI | Common Stock | Award | 0.44% | 561 | 128,319 | 30 Jun 2026 | Direct | ||
| Richard Henry Marshall | TLSI | Common Stock | Award | 200% | 60,000 | 90,000 | 29 Jun 2026 | Direct | ||
| Richard Henry Marshall | TLSI | Employee Stock Option (right to buy) | Award | 90.2% | 120,000 | 253,000 | 29 Jun 2026 | Direct | ||
| Richard Marshak | TLSI | Common Stock | Sale | -0.43% | -$1,450 | $2.67 | -543 | 125,101 | 15 May 2026 | Direct |
| Mats Wahlstrom | TLSI | Common Stock | Purchase | 68.5% | $151,800 | $2.53 | 60,000 | 147,555 | 15 May 2026 | Direct |
| Michael P. Stansky | TLSI | Common Stock | Purchase | 100.2% | $500,000 | $2.50 | 200,000 | 399,698 | 15 May 2026 | By Skyview Investments LLC |
| Michael P. Stansky | TLSI | Common Stock | Purchase | 49.4% | $1,025,000 | $2.50 | 410,000 | 1,240,722 | 15 May 2026 | Direct |
| Szela Mary T. | TLSI | Common Stock | Purchase | 3.87% | $102,776 | $2.59 | 39,682 | 1,065,215 | 15 May 2026 | Direct |
| David Patience | TLSI | Common Stock | Purchase | 2.64% | $17,253 | $2.43 | 7,100 | 275,757 | 15 May 2026 | Direct |
| Gary B. Gordon | TLSI | Common Stock | Purchase | 16% | $24,600 | $2.46 | 10,000 | 72,510 | 15 May 2026 | Direct |
| Kerry R. Hicks | TLSI | Common Stock | Award | 5.48% | 28,201 | 542,790 | 14 May 2026 | Direct | ||
| Kerry R. Hicks | TLSI | Director Stock Option (right to buy) | Award | 63.2% | 56,403 | 145,625 | 14 May 2026 | Direct | ||
| Mats Wahlstrom | TLSI | Common Stock | Award | 456.7% | 71,828 | 87,555 | 14 May 2026 | Direct | ||
| Mats Wahlstrom | TLSI | Director Stock Option (right to buy) | Award | 37.4% | 75,204 | 276,149 | 14 May 2026 | Direct | ||
| Gary B. Gordon | TLSI | Common Stock | Award | 540.7% | 52,754 | 62,510 | 14 May 2026 | Direct | ||
| Gary B. Gordon | TLSI | Director Stock Option (right to buy) | Award | 100.3% | 56,403 | 112,653 | 14 May 2026 | Direct | ||
| David J. Matlin | TLSI | Common Stock | Award | 4.03% | 51,266 | 1,323,210 | 14 May 2026 | Direct | ||
| David J. Matlin | TLSI | Director Stock Option (right to buy) | Award | 86.8% | 56,403 | 121,403 | 14 May 2026 | Direct | ||
| William Valle | TLSI | Common Stock | Award | 173% | 52,754 | 83,241 | 14 May 2026 | Direct | ||
| William Valle | TLSI | Director Stock Option (right to buy) | Award | 100.3% | 56,403 | 112,653 | 14 May 2026 | Direct | ||
| Michael P. Stansky | TLSI | Common Stock | Award | 5.54% | 43,590 | 830,722 | 14 May 2026 | Direct | ||
| Michael P. Stansky | TLSI | Director Stock Option (right to buy) | Award | 50.8% | 47,003 | 139,540 | 14 May 2026 | Direct | ||
| Szela Mary T. | TLSI | Common Stock | Sale | -2.07% | -$61,384 | $3.85 | -15,944 | 752,987 | 17 Mar 2026 | Direct |
| Jodi Devlin | TLSI | Common Stock | Sale | -0.28% | -$1,125 | $4.12 | -273 | 97,364 | 16 Mar 2026 | Direct |
| Bryan F. Cox | TLSI | Common Stock | Sale | -0.35% | -$2,385 | $4.12 | -579 | 163,415 | 16 Mar 2026 | Direct |
| Richard Marshak | TLSI | Common Stock | Sale | -0.38% | -$1,726 | $4.12 | -419 | 110,397 | 16 Mar 2026 | Direct |
| Jennifer Stevens | TLSI | Common Stock | Sale | -0.62% | -$3,189 | $4.12 | -774 | 124,110 | 16 Mar 2026 | Direct |
| Jodi Devlin | TLSI | Common Stock | Sale | -1.78% | -$7,247 | $4.09 | -1,772 | 97,637 | 12 Mar 2026 | Direct |
| Bryan F. Cox | TLSI | Common Stock | Sale | -0.89% | -$6,000 | $4.09 | -1,467 | 163,994 | 12 Mar 2026 | Direct |
| Richard Marshak | TLSI | Common Stock | Sale | -1.41% | -$6,499 | $4.09 | -1,589 | 110,816 | 12 Mar 2026 | Direct |
| Jennifer Stevens | TLSI | Common Stock | Sale | -1.23% | -$6,348 | $4.09 | -1,552 | 124,884 | 12 Mar 2026 | Direct |
| Jodi Devlin | TLSI | Common Stock | Sale | -1.16% | -$4,799 | $4.13 | -1,162 | 99,409 | 11 Mar 2026 | Direct |
| Bryan F. Cox | TLSI | Common Stock | Sale | -0.68% | -$4,700 | $4.13 | -1,138 | 165,461 | 11 Mar 2026 | Direct |
| Richard Marshak | TLSI | Common Stock | Sale | -1.27% | -$5,984 | $4.13 | -1,449 | 112,405 | 11 Mar 2026 | Direct |
| Jennifer Stevens | TLSI | Common Stock | Sale | -0.94% | -$4,973 | $4.13 | -1,204 | 126,436 | 11 Mar 2026 | Direct |
| Szela Mary T. | TLSI | Common Stock | Sale | -0.56% | -$17,999 | $4.13 | -4,358 | 768,931 | 11 Mar 2026 | Direct |
| David Patience | TLSI | Common Stock | Purchase | 1.38% | $14,994 | $4.10 | 3,657 | 268,657 | 23 Feb 2026 | Direct |
| Gary B. Gordon | TLSI | Common Stock | Purchase | $40,000 | $4.10 | 9,756 | 9,756 | 23 Feb 2026 | Direct | |
| William Valle | TLSI | Common Stock | Purchase | $124,997 | $4.10 | 30,487 | 30,487 | 23 Feb 2026 | Direct | |
| Szela Mary T. | TLSI | Common Stock | Purchase | 4.1% | $124,997 | $4.10 | 30,487 | 773,289 | 23 Feb 2026 | Direct |
| Michael P. Stansky | TLSI | Common Stock | Purchase | 142.1% | $480,512 | $4.10 | 117,198 | 199,698 | 23 Feb 2026 | By LLC |
| Michael P. Stansky | TLSI | Common Stock | Purchase | 44.9% | $999,990 | $4.10 | 243,900 | 787,132 | 23 Feb 2026 | Direct |
| Michael P. Stansky | TLSI | Director Stock Option (right to buy) | Award | 92,537 | 92,537 | 04 Feb 2026 | Direct | |||
| Szela Mary T. | TLSI | Common Stock | Award | 0.21% | 2,100 | 1,023,826 | 31 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.